Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms

Translational Research

Volumn 149, Issue 3, 2007, Pages 137-144

  Nanni, Samuele ^a   Melandri, Giovanni ^a   Hanemaaijer, Roeland ^b   Cervi, Vittorio ^a   Tomasi, Luciana ^a   Altimari, Annalisa ^a   Van Lent, Natascha ^b   Tricoci, Pierluigi ^a   Bacchi, Letizia ^a   Branzi, Angelo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GELATINASE A; GELATINASE B; GLUCOSE; HAPTOGLOBIN; MATRIX METALLOPROTEINASE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; EXON; GENETIC POLYMORPHISM; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

ADULT; C-REACTIVE PROTEIN; CORONARY ARTERY DISEASE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPTOGLOBINS; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 33847060059     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2006.09.001     Document Type: Article

References (25)

1. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 104 (2001) 365-372
2. Galis Z.S., and Khatri J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90 (2002) 251-262
3. Ye S., Eriksson P., Hamsten A., Kurkinen M., Humphries S.E., and Henney A.M. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem 271 (1996) 13055-13060
4. Zhang B., Ye S., Herrmann S.M., Eriksson P., de Maat M., Evans A., et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 99 (1999) 1788-1794
5. Ye S., Watts G.F., Mandalia S., Humphries S.E., and Henney A.M. Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J 73 (1995) 209-215
6. Zhang B., Henney A., Eriksson P., Hamsten A., Watkins H., and Ye S. Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2-13.1. Hum Genet 105 (1999) 418-423
7. de Maat M.P., Jukema J.W., Ye S., Zwinderman A.H., Moghaddam P.H., Beekman M., et al. Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. Am J Cardiol 83 (1999) 852-856
8. Humphries S.E., Luong L.A., Talmud P.J., Frick M.H., Kesaniemi Y.A., Pasternack A., et al. The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. Lopid Coronary Angiography Trial. Atherosclerosis 139 (1998) 49-56
9. Yamada Y., Izawa H., Ichihara S., Takatsu F., Ishihara H., Hirayama H., et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 347 (2002) 1916-1923
10. Terashima M., Akita H., Kanazawa K., Inoue N., Yamada S., Ito K., et al. Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction. Circulation 99 (1999) 2717-2719
11. Pollanen P.J., Karhunen P.J., Mikkelsson J., Laippala P., Perola M., Penttila A., et al. Coronary artery complicated lesion area is related to functional polymorphism of matrix metalloproteinase 9 gene: an autopsy study. Arterioscler Thromb Vasc Biol 21 (2001) 1446-1450
12. Tunstall-Pedoe H., Kuulasmaa K., Amouyel P., Arveiler D., Rajakangas A.M., and Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 90 (1994) 583-612
13. Hanemaaijer R., Visser H., Konttinen Y.T., Koolwijk P., and Verheijen J.H. A novel and simple immunocapture assay for determination of gelatinase- B (MMP-9) activities in biological fluids: saliva from patients with Sjogren's syndrome contain increased latent and active gelatinase-B levels. Matrix Biol 17 (1998) 657-665
14. Capper S.J., Verheijen J., Smith L., Sully M., Visser H., and Hanemaaijer R. Determination of gelatinase-A (MMP-2) activity using a novel immunocapture assay. Ann NY Acad Sci 878 (1999) 487-490
15. Kai H., Ikeda H., Yasukawa H., Kai M., Seki Y., Kuwahara F., et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 32 (1998) 368-372
16. Inokubo Y., Hanada H., Ishizaka H., Fukushi T., Kamada T., and Okumura K. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 141 (2001) 211-217
17. Lamblin N., Bauters C., Hermant X., Lablanche J.M., Helbecque N., and Amouyel P. Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease. J Am Coll Cardiol 40 (2002) 43-48
18. Gnasso A., Motti C., Irace C., Carallo C., Liberatoscioli L., Bernardini S., et al. Genetic variation in human stromelysin gene promoter and common carotid geometry in healthy male subjects. Arterioscler Thromb Vasc Biol 20 (2000) 1600-1605
19. Hirohata S., Kusachi S., Murakami M., Murakami T., Sano I., Watanabe T., et al. Time dependent alterations of serum matrix metalloproteinase-1 and metalloproteinase-1 tissue inhibitor after successful reperfusion of acute myocardial infarction. Heart 78 (1997) 278-284
20. Noji Y., Kajinami K., Kawashiri M.A., Todo Y., Horita T., Nohara A., et al. Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. Clin Chem Lab Med 39 (2001) 380-384
21. Smeets M.B., De Kleijn D.P.V., Poppen M., Lim S.K., Pasterkamp G., and Borst C. The acute phase protein haptoglobin is a matrix metalloproteinase-2 inibitor. Circulation 102 (2000) 835
22. Maxwell P.R., Timms P.M., Chandran S., and Gordon D. Peripheral blood level alterations of TIMP-1, MMP-2 and MMP-9 in patients with type 1 diabetes. Diabet Med 18 (2001) 777-780
23. Singh R., Song R.H., Alavi N., Pegoraro A.A., Singh A.K., and Leehey D.J. High glucose decreases matrix metalloproteinase-2 activity in rat mesangial cells via transforming growth factor-beta1. Exp Nephrol 9 (2001) 249-257
24. Kuzuya M., Asai T., Kanda S., Maeda K., Cheng X.W., and Iguchi A. Glycation cross-links inhibit matrix metalloproteinase-2 activation in vascular smooth muscle cells cultured on collagen lattice. Diabetologia 44 (2001) 433-436
25. Kalela A., Laaksonen R., Lehtimaki T., Koivu T.A., Hoyhtya M., Janatuinen T., et al. Effect of pravastatin in mildly hypercholesterolemic young men on serum matrix metalloproteinases. Am J Cardiol 88 (2001) 173-175 A6